Floatz logo

Nivestim

Smoldering Plasma Cell Myeloma

Regeneron Pharmaceuticalsprotein_peptidePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Smoldering Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
Dexasone
Regeneron Pharmaceuticals
Phase 3BB
Linvoseltamab
Regeneron Pharmaceuticals
Phase 3BB
LENALIDOMIDE
Irene Ghobrial, MD
Phase 3BB
DARATUMUMAB
Regeneron Pharmaceuticals
Phase 3BB
Cyclophosphamide
Dana-Farber Cancer Institute
Phase 2B

View all 47 →

Same molecule, other indications

Nivestim is also rated in:

Burkitt lymphomaActive
BBB
Indicative · Phase 4
78 / 100
View asset →
neutropeniaActive
BBB
Indicative · Phase 4
76 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative · Phase 4
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →